BTTC News
Houston, TX - January 23, 2009
BTTC Annual Meeting
The Annual BTTC Meeting was held on January 23, 2009 at University of
Texas M. D. Anderson Cancer Center. The meeting welcomed our doctors
from their respective institutions, as well as from the newly joined
institutions. We discussed the enormous progress the collaborative has
achieved in its relatively short life so far from the legal and logistical
obstacles passed, to beginning enrollment into research protocols. We
also discussed our collaborative making headway in our profile through
the internet, as well as integration of technology into its operations.
The BTTC08-01 trial is underway. As of the week of July 13, 2009 we
have three subjects registered in the study. All are in Dr. Raizer's
site — Northwestern University, with M. D. Anderson expecting enrollment
fairly soon.
The Temodar Combination Study was integrated into the collaborative
earlier this year, and has now reached an enrollment of over 120 patients,
thanks to the participation of BTTC sites.
The BTTC has a potential vaccine protocol in the pipeline. The proposal
was presented by Dr. John Yu of Cedars-Sinai, and is being reviewed.
It was originally introduced during our annual meeting earlier this year.
We also have another potential protocol. A Sorafenib/RAD001 study by
Drs. Raizer and Grimm of Northwestern University is undergoing the review
process right now.
The Data Management team at M. D. Anderson is hard at work creating
an online Protocol Data Management system that will automate protocol
management for studies conducted by BTTC member institutions. It is in
the 'beta' stage now, but expected to be released by the end of the year.